Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0677481 (urinary frequency)
 1,126 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Forty patients with carcinoma in situ of the bladder were reviewed. They included 15 patients with primary carcinoma in situ, 8 with secondary carcinoma in situ and 17 with concurrent carcinoma in situ. Twenty-one (66%) of 32 patients with primary or concurrent carcinoma in situ complained of urinary frequency and pain on urination, whereas no patients with secondary carcinoma in situ complained of such symptoms. Nearly all patients with concurrent or secondary carcinoma in situ had gross hematuria, whereas only 7 (47%) of 15 patients with primary carcinoma in situ had gross hematuria. Two patients without any symptoms were diagnosed by incidental positive urinary cytology. Concurrent carcinoma in situ was always associated with multiple papillary tumor. Dominant grade of the papillary tumor was classified as grade 3 in 11 patients and as grade 2 in 6. The simultaneous presence of carcinoma in situ of the urethra was found in 13 (46%) patients and those of the ureter in 17 (74%). Fourteen patients (35%) with carcinoma in situ developed an invasive carcinoma. Of these, 4 (10%) died of cancer. Bacillus calmette-guerin instillation was effective in 13 of 15 patients (87%). These results indicate that carcinoma in situ of the bladder may develop an invasive cancer, may remain in the epithelia, or may be associated with multiple superficial tumor. It should be emphasized that patients with multiple superficial bladder tumor may be associated with carcinoma in situ even if the superficial tumors are of low grade and urine cytology is negative.
 ...
PMID:[The progress pattern of carcinoma in situ of the urinary bladder]. 192 Oct 16

Observations are presented on 9 patients recently treated in the University Teaching Hospital, Lusaka, Zambia, for painful urinary frequency, suprapubic pain and microscopic and/or macroscopic haematuria without any demonstrable urinary tract infection. At cystoscopy the bladder mucosa of all patients depicted a highly characteristic, uniformly congested appearance with no demonstrable ulcers; there was no significant reduction in bladder capacity. The histological appearance was essentially non-specific in type with an apparent resemblance to that of interstitial cystitis; mast cells were, however, absent in all specimens. An important feature common to all patients was an associated HIV infection; cytochemistry of the bladder tissue did not reveal an associated cytomegalovirus cystitis. No such case was observed in Zambia prior to the advent of HIV infection and the phenomenon was observed only in seropositive patients. It has been suggested that the virus is likely to be associated with the genesis of the bladder symptoms. The natural history of the disorder, its incidence among the seropositive individuals and its pathogenesis remain unclear.
 ...
PMID:Haematuria frequency syndrome in patients with positive HIV serology: observations in Zambia. 200 24

The signs and symptoms produced by 4 different types of 7F double pigtail catheters, including Cook polyurethane pigtail stent, Surgitek Silitek Uropass, Cook C-Flex and Van-Tec Soft stent, were analyzed prospectively. The stents were placed in 45 men and 28 women ranging in age from 23 to 72 years old. A total of 44 catheters had a suture attached to the bladder end of the catheter, which exited from the urethral meatus to facilitate removal. The remaining 29 catheters had no suture attached. Symptoms were evaluated at 2 and 6 days after insertion and 1 week following removal of the catheter, and included urinary frequency, nocturia, hematuria, flank pain, suprapubic pain, dysuria and pain on removal of the catheter. Frequency and nocturia were evaluated in minutes, pain was graded on a subjective scale of 0 (no pain) to 10 (severe pain), and dysuria and hematuria were assessed qualitatively. There were no significant differences among the 4 types of catheters in terms of frequency, nocturia, hematuria, flank pain, suprapubic pain and dysuria. In addition, there was no significant difference in urinary symptoms between catheters with and without a suture at either 2 or 6 days after insertion nor was there any difference in pain on removal of catheters with (mean 3.9) and without (mean 5.0) suture. We found that catheter composition and use of suture to facilitate removal did not significantly affect patient morbidity.
 ...
PMID:Comparison of symptom characteristics of indwelling ureteral catheters. 200 86

Seven women who underwent the Stamey endoscopic bladder neck suspension performed by different urologists at a variety of institutions were evaluated at the Lahey Clinic Medical Center. Two to 36 months after operation, each woman sought medical attention because of complaints of pain in the lower abdomen, pelvis, or groin with or without urinary frequency and urgency. Endoscopic examination revealed an acute mucosal inflammatory reaction, perforating sutures or Dacron pledgets, and formation of calculi around a suture. In each patient, sutures or pledgets were removed endoscopically with resolution of presenting complaints.
 ...
PMID:Complications of retropubic bladder neck suspension. 218 Jan 72

A 30-year-old white woman with urinary frequency, left costovertebral angle pain and hematuria had left hydronephrosis, a marked decrease in bladder capacity and severe eosinophilic cystitis on biopsy. She was treated with a nonsteroidal anti-inflammatory drug and an antihistamine, with a dramatic, complete and rapid recovery. The nonsteroidal anti-inflammatory drug was believed to have been responsible for the favorable outcome, since antihistamines have not produced reliable benefits in this disease. Nonsteroidal anti-inflammatory drugs are recommended in cases of eosinophilic cystitis.
 ...
PMID:Nonsteroidal anti-inflammatory drugs in the treatment of eosinophilic cystitis. 223 45

Double-pigtail stents are placed commonly in patients before extracorporeal shock wave lithotripsy to prevent ureteral obstruction from steinstrasse. The use of double-pigtail stents in lithotripsy patients with a moderate stone burden was studied in a prospective randomized trial. Patients with unilateral renal stone(s) with at least 1 diameter between 7 and 25 mm. were eligible for the study. Fifty patients were randomized to a control or stented group. Double-pigtail stents with an attached suture were placed immediately before extracorporeal shock wave lithotripsy in the stented group. Stents were removed by the patients 1 week after lithotripsy. A survey on pain and associated symptoms was completed by patients at 1 and 14 days after treatment. There was no statistical difference in flank or abdominal pain, nausea, vomiting, temperature or use of analgesics at 1 and 14 days after extracorporeal shock wave lithotripsy in the control and stented groups. All patients in the stented groups complained of side effects attributable to the stent including urinary frequency and urgency, bladder pain, hematuria and flank pain with urination. Of 25 patients with stents 7 (27%) had early removal because of severe irritation, early migration or accidental removal. Among the patients with follow-up x-rays 1 month after treatment 17 of 21 (81%) in the control group and 12 of 19 (63%) in the stented group showed no evidence of remaining stones. The use of double-pigtail stents is not beneficial in patients with a moderate stone burden. Double-pigtail stents are associated with considerable patient discomfort but no decrease in symptomatic ureteral obstruction or final stone eradication rate.
 ...
PMID:Use of double-pigtail stents in extracorporeal shock wave lithotripsy. 240 62

In order to examine its clinical efficacy, recombinant human interferon-beta (rIFN-beta) was instilled intravesically into 51 patients with superficial bladder cancer. Ten patients, who received intermittent intravesical instillation at a dose of (3-36) x 10(6) U rIFN-beta on days 1-3 every week, showed no response. Thirty-two patients received intravesical instillation at a dose of (3-36) x 10(6) U every day for 10-20 days. Eight patients showed partial response, indicating an efficacy rate of 25%. Nine patients received divided doses of 18 x 10(6) U twice a day every day for 10-20 days. Six patients showed partial response, indicating an efficacy rate of 67%. This value was significantly higher than that obtained by administering divided doses. The response to intravesical instillation therapy with rIFN-beta varies with treatment protocol. Frequent and longer exposure to rIFN-beta may induce better regression of superficial bladder cancer. Six incidences of side-effects were found in five cases (9.8%): pollakiuria in one, pain on micturition in two, fever in two, and eruption in one case. All of these side-effects were slight and reversible after drug withdrawal. Laboratory tests showed only a few changes with low severity. Thus, rIFN-beta is potentially a new drug for instillation therapy of superficial bladder cancer, in view of the absence of adverse effects.
 ...
PMID:Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group. 259 81

A 76-year-old woman presented with a history of pain on urination and urinary frequency. The sonogram incidentally demonstrated a mass in the area of the upper right kidney, and CT scan revealed a retroperitoneal tumor. Operation was carried out, and the tumor measured 4 X 4 X 5.5 cm (35 g). The pathology report was consistent with leiomyoma. The patient had undergone surgical excision of a right retroperitoneal tumor before 27 years, and it is suspected to have been an ectopic retroperitoneal tumor judging from operative findings. Retroperitoneal leiomyoma is rare and a review of the Japanese literature is presented.
 ...
PMID:[A case report of retroperitoneal leiomyoma and review of the Japanese literature]. 268 33

A case is reported of intravesical placement of a vaginal contraceptive suppository. 2 previously reported cases involving the same brand of suppository and treatment recommendations are reviewed. A 29-year-old woman inserted a contraceptive suppository 15 minutes prior to intercourse. Subsequently, she noticed transient, poorly localized burning that had not been present before she used the suppository. The woman had no history of urinary tract infection or similar symptoms. She awakened 4 hours later with intense urethral pain and inability to void. Catheterization was performed 1 hour later, yielding grossly bloody urine, following which she was able to urinate. Pelvic examination was normal, and an x-ray was negative for a foreign body. The patient complained of severe urgency, frequency, and terminal dysuria 3 days later at follow-up. Physical examination revealed a normally placed urethral meatus calibrated at 21 degrees Fahrenheit. Cystoscopic findings were remarkable for a pale, edematous trigone that stood in sharp contrast to an erythematous pancystitis in the remaining bladder mucosa. No foreign body was present. Capacity was 100 cc, above which marked pain was experienced. The urethral mucosa was inflamed. The patient was treated with trimethoprim-sulfamethoxazole and 50 mg prednisone orally, which was tapered to 10 mg/day. The symptoms persisted 6 days after the mishap with urinary frequency every 30 minutes. Urine culture was sterile. The patient was given 50 mg methylprednisolone sodium succinate in 50 cc sterile water intravesically for 1 hour along with antispasmodics. The patient was asymptomatic by day 14. The clinical findings resemble previously reported cases. The patient had no similar symptoms before or since this episode. Since the urine culture was sterile, and the patient was not taking antibiotics, there was no apparent reason for the severe cystitis. It is strongly believed that urethral insertion of the suppository was the etiology of the symptoms.
 ...
PMID:Inadvertent urethral insertion of a contraceptive suppository. 283 68

Transcatheter arterial embolization was performed in a total of 70 patients with invasive bladder cancer from October 1980 to December 1987. It was performed as a part of multidisciplinary treatment in patients with invasive bladder cancer. Microencapsulated mitomycin C, gelatin sponge and lipiodol (iodized oil) were used as the embolic material. As a result, reduction of tumor size was noted in 56.7%, but there was no embolic materials-related significant difference. Stage reduction was noted in 72.7% of patients where pathological stages were confirmed by operation. Hemostatic effects were noted in 76.5%. The symptoms of side effects included fever, leukocytosis, urinary frequency and pain, but none of them was severe. The results of the present study indicate that embolization of the vesical artery is useful in the treatment of bladder cancer.
 ...
PMID:Transcatheter arterial embolization of vesical artery in the treatment of invasive bladder cancer. 285 Sep 18


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>